Printer Friendly

UPJOHN APPEALS HALCION SUSPENSION TO U.K. MEDICINES COMMISSION

 UPJOHN APPEALS HALCION SUSPENSION TO U.K. MEDICINES COMMISSION
 KALAMAZOO, Mich., Dec. 16 /PRNewswire/ -- The Upjohn Company (NYSE: UPJ) was notified that the United Kingdom's Committee on Safety of Medicines (CSM) recommended to the Medicines Control Agency (MCA) that the product license for Halcion be revoked.
 "We continue to believe that U.K. authorities acted precipitously in removing Halcion in October," said Upjohn Chairman and Chief Executive Officer Theodore Cooper, M.D., Ph.D. "We intend to pursue the appeal and to exercise all rights and options."
 The United Kingdom originally suspended sales of the product Oct. 2. The CSM's recent action came in response to an Upjohn appeal hearing Dec. 3. Per established procedures of the Medicines Act, Upjohn has 28 days to request an appeal hearing before the Medicines Commission.
 The Medicines Commission, which functions as the principal advisory committee on all aspects of the U.K. Medicines Act, will be asked to undertake a complete review of Halcion safety data and to make recommendations to the U.K. licensing authority.
 In the two months since the U.K. suspension, both the European Community's Committee for Proprietary Medicinal Products (CPMP) and the United States Food and Drug Administration (FDA) have undertaken reviews of Halcion. The CPMP announced following its Dec. 11 meeting that it supports the Halcion labeling and packaging changes that it recommended in October, while confirming the "absolute importance" of short-term use of the product. In addition, the committee directed its working group to expand its review from Halcion to all short-acting sleeping medications.
 The FDA in November approved new labeling and packaging for Halcion, including a patient information leaflet, which advises consumers on the proper use of the medication.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 12/16/91
 /CONTACT: Kaye P. Bennett, 616-323-4224, or Philip R. Sheldon, 616-323-6318, both of The Upjohn Company/
 (UPJ) CO: The Upjohn Company ST: Michigan IN: MTC SU:


JG -- DE005 -- 2418 12/16/91 10:09 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 16, 1991
Words:363
Previous Article:J. MICHAEL KELLY NAMED VICE PRESIDENT AND CONTROLLER FOR GTE
Next Article:WRITER/DIRECTOR/ACTOR ROBERT TOWNSEND AND ACTRESS/AUTHOR RUBY DEE DO DRAMATIC READINGS FOR PAL KIDS TO SUPPORT LITERACY
Topics:


Related Articles
UPJOHN ANNOUNCES NEW U.S. PACKAGING AND LABELING FOR HALCION
UPJOHN RESPONSE TO HALCION TV CHARGES
SPAIN TAKES ACTION ON HALCION
ADVISORY COMMISSION RECOMMENDS HALCION RETURN TO U.K. MARKET
UPJOHN RESPONDS TO WOLFE FDA LETTER
UPJOHN TAKES U.K. GOVERNMENT BODY TO COURT OVER HALCION
PRESCRIPTION PROGRAM LIMITS REIMBURSEMENT FOR RESTORIL
SPORANOX SETS RECORDS FOR CONSUMER RESPONSE AND PRESCRIPTIONS FOR TREATMENT OF TOENAIL FUNGUS
PHARMACIA & UPJOHN RESPONDS TO FDA HALCION REPORT
FDA CLEARS NEW CANCER DRUG, CAMPTOSAR(TM) INJECTION FOR MARKET

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters